Stemline Therapeutics, a biotech developing treatments that target cancer stem cells and tumor bulk, postponed its IPO on Tuesday. The New York, NY-based company had been planning to raise $42 million at a price range of $11 to $13. RBC Capital Markets, Oppenheimer & Co. were set to be the joint bookrunners on the deal.
